Strs Ohio Acquires Shares of 32,400 Corcept Therapeutics Incorporated (NASDAQ:CORT)

Strs Ohio acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORTGet Rating) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 32,400 shares of the biotechnology company’s stock, valued at approximately $830,000.

A number of other institutional investors have also added to or reduced their stakes in CORT. JPMorgan Chase & Co. grew its holdings in Corcept Therapeutics by 2.4% during the 1st quarter. JPMorgan Chase & Co. now owns 216,081 shares of the biotechnology company’s stock valued at $4,866,000 after buying an additional 5,036 shares in the last quarter. American Century Companies Inc. grew its holdings in Corcept Therapeutics by 8.2% during the 1st quarter. American Century Companies Inc. now owns 88,553 shares of the biotechnology company’s stock valued at $1,994,000 after buying an additional 6,684 shares in the last quarter. Citigroup Inc. grew its holdings in Corcept Therapeutics by 15.0% during the 1st quarter. Citigroup Inc. now owns 103,241 shares of the biotechnology company’s stock valued at $2,325,000 after buying an additional 13,488 shares in the last quarter. Natixis Advisors L.P. grew its holdings in Corcept Therapeutics by 56.7% during the 1st quarter. Natixis Advisors L.P. now owns 18,581 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 6,726 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in Corcept Therapeutics by 3.3% during the 1st quarter. Acadian Asset Management LLC now owns 31,845 shares of the biotechnology company’s stock valued at $716,000 after buying an additional 1,032 shares in the last quarter. 80.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Gary Charles Robb sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $26.06, for a total value of $260,600.00. Following the completion of the sale, the insider now directly owns 39,544 shares in the company, valued at $1,030,516.64. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Gary Charles Robb sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $26.06, for a total value of $260,600.00. Following the completion of the sale, the insider now directly owns 39,544 shares in the company, valued at $1,030,516.64. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sean Maduck sold 25,000 shares of the firm’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $25.57, for a total value of $639,250.00. Following the completion of the sale, the insider now owns 56,462 shares of the company’s stock, valued at $1,443,733.34. The disclosure for this sale can be found here. Insiders sold a total of 40,439 shares of company stock worth $1,040,958 over the last three months. 18.60% of the stock is owned by insiders.

Analysts Set New Price Targets

CORT has been the subject of a number of recent research reports. HC Wainwright cut their target price on shares of Corcept Therapeutics from $33.00 to $30.00 and set a “buy” rating for the company in a report on Friday, December 9th. StockNews.com raised shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 27th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Corcept Therapeutics has an average rating of “Buy” and a consensus target price of $31.25.

Corcept Therapeutics Stock Performance

CORT stock opened at $22.44 on Monday. The firm has a market cap of $2.42 billion, a PE ratio of 22.44 and a beta of 0.59. The firm has a fifty day moving average price of $22.87 and a 200 day moving average price of $25.51. Corcept Therapeutics Incorporated has a fifty-two week low of $16.47 and a fifty-two week high of $30.14.

Corcept Therapeutics (NASDAQ:CORTGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.07. The company had revenue of $101.73 million during the quarter, compared to the consensus estimate of $107.73 million. Corcept Therapeutics had a return on equity of 27.49% and a net margin of 29.37%. On average, equities analysts predict that Corcept Therapeutics Incorporated will post 0.89 EPS for the current year.

Corcept Therapeutics Company Profile

(Get Rating)

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

Featured Articles

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.